Questions

1804. Deputy Ken O'Flynn asked the Minister for Health whether the HSE records data regarding minors presenting to gender-related healthcare pathways who are awaiting autism assessment, ADHD assessment, CAMHS intervention, or other specialist neurodevelopmental or mental health assessment at the time of referral; and if they will provide details. [41661/26]

1808. Deputy Ken O'Flynn asked the Minister for Health whether Children First obligations, safeguarding frameworks, or specific child protection procedures form part of the operational governance framework for minors presenting to gender-related healthcare pathways; and if they will provide details. [41665/26]

1810. Deputy Ken O'Flynn asked the Minister for Health whether the HSE maintains any longitudinal outcome-monitoring framework relating to minors who access gender-related healthcare pathways, including continuation or discontinuation of treatment pathways, mental health outcomes, safeguarding concerns, ongoing service engagement, or transition between child and adult services; and if they will provide details. [4166…

1811. Deputy Ken O'Flynn asked the Minister for Health whether her Department, the HSE, or any State-funded body has commissioned, conducted, or reviewed Irish epidemiological, clinical, or service-level research concerning the prevalence of autism spectrum disorder, ADHD, trauma-related conditions, mental health comorbidities, or other neurodevelopmental vulnerabilities among minors presenting with gender-related di…

1812. Deputy Ken O'Flynn asked the Minister for Health whether international evidence reviews relating to youth gender-related healthcare, including reviews examining neurodevelopmental comorbidity, multidisciplinary assessment, safeguarding, and holistic care models, have informed the development of Irish policy, governance structures, or service models in this area; and if they will specify the reviews considered. …

1814. Deputy Ken O'Flynn asked the Minister for Health whether any national audit, review, inspection, governance assessment, or external evaluation has been undertaken in relation to gender-related healthcare pathways involving minors within the State; and if they will provide details of the findings and recommendations. [41671/26]

1821. Deputy Ken O'Flynn asked the Minister for Health whether documentary records exist including minutes, memoranda, briefing papers, internal correspondence, emails, governance submissions, or evidential assessments concerning the inclusion of WPATH Standards of Care references within the 2019 CAAC application; and whether such records will be retained under HSE records management and governance procedures. [41688…

1839. Deputy Ken O'Flynn asked the Minister for Health whether the Department or HSE has undertaken any modelling of the projected annual eligible population for reimbursement of tirzepatide or semaglutide for obesity treatment over the next five years. [41712/26]

1840. Deputy Ken O'Flynn asked the Minister for Health whether any estimate has been produced of the potential annual Exchequer cost associated with reimbursement of obesity pharmacotherapies under current licensing criteria. [41713/26]

1841. Deputy Ken O'Flynn asked the Minister for Health whether any national eligibility framework, prioritisation framework, or phased access model is under development for obesity pharmacotherapy reimbursement. [41714/26]

1842. Deputy Ken O'Flynn asked the Minister for Health whether multidisciplinary assessment, psychological screening, or behavioural intervention participation will be mandatory prior to reimbursement approval for obesity pharmacotherapies. [41715/26]

1843. Deputy Ken O'Flynn asked the Minister for Health whether any assessment has been undertaken of the long-term fiscal sustainability of reimbursing GLP-1 and dual agonist obesity therapies within the public health system. [41716/26]

1845. Deputy Ken O'Flynn asked the Minister for Health whether any estimate has been produced of the projected number of adolescent patients who could potentially meet the proposed reimbursement criteria for semaglutide. [41718/26]

1903. Deputy Ken O'Flynn asked the Minister for Health to identify the specific unit, division or named office within her Department responsible for governance oversight of the treatment abroad scheme. [41870/26]

1905. Deputy Ken O'Flynn asked the Minister for Health the dates on which the treatment abroad scheme was audited by HSE Internal Audit since 2020; and whether any recommendations were issued following those audits. [41872/26]

2029. Deputy Ken O'Flynn asked the Minister for Health whether the HSE or Department of Health has engaged with professional regulators, including the Medical Council, Nursing and Midwifery Board of Ireland, CORU, or Dental Council, regarding information-sharing arrangements where registrants are subject to criminal investigation for serious offences; and if she will make a statement on the matter. [42442/26]

2198. Deputy Ken O'Flynn asked the Minister for Health whether her Department's quarterly oversight meetings with the Treatment Abroad Scheme include consideration of governance, patient safety, safeguarding or clinical outcome matters relating to minors, in addition to activity and expenditure. [43248/26]

691. Deputy Ken O'Flynn asked the Minister for Health whether any external professional body, advocacy organisation, international clinical body, or external adviser was consulted regarding the wording or clinical framework used within the 2019 CAAC application relating to the consultant child and adolescent psychiatry post. [41260/26]

697. Deputy Ken O'Flynn asked the Minister for Health the membership, reporting structure, and terms of reference of the SCAN steering group referenced by HSE South-West. [41266/26]

699. Deputy Ken O'Flynn asked the Minister for Health further to Parliamentary Question No. 539 of 19 February, whether any formal national clinical governance approval process existed governing the inclusion of WPATH Standards of Care Version 7 within the Consultant Applications Advisory Committee submission; and to identify each HSE or Departmental governance body involved in reviewing or approving that inclusion. …

701. Deputy Ken O'Flynn asked the Minister for Health further to Parliamentary Question No. 539 of 19 February, whether any written evidential review, literature review, clinical assessment, governance memorandum, safety analysis, or policy briefing was prepared specifically concerning reliance upon WPATH Standards of Care Version 7 during preparation or approval of the Consultant Applications Advisory Committee subm…

702. Deputy Ken O'Flynn asked the Minister for Health further to Parliamentary Question No. 539 of 19 February, whether any formal risk assessment was conducted regarding the proposed use of WPATH Standards of Care Version 7 within child and adolescent gender healthcare services in advance of approval of the consultant psychiatry post referenced; and if so, the date and authorship of that assessment. [41271/26]

703. Deputy Ken O'Flynn asked the Minister for Health further to Parliamentary Question No. 539 of 19 February, whether any concerns, reservations, objections, dissenting opinions, or governance queries were raised internally regarding reliance upon WPATH Standards of Care Version 7 during the preparation, review, or approval process relating to the consultant child and adolescent psychiatry post referenced. [41272/2…

705. Deputy Ken O'Flynn asked the Minister for Health further to Parliamentary Question No. 539 of 19 February, whether any minutes, records, file notes, meeting notes, internal correspondence, or email communications exist concerning the decision to reference WPATH Standards of Care Version 7 within the Consultant Applications Advisory Committee submission referenced. [41274/26]

706. Deputy Ken O'Flynn asked the Minister for Health further to Parliamentary Question No. 539 of 19 February, whether any legal advice was sought, obtained, or considered concerning the proposed reliance upon WPATH Standards of Care Version 7 in connection with the consultant child and adolescent psychiatry post referenced. [41275/26]